Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVL006 + enfortumab vedotin
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CVL006 + enfortumab vedotin is an investigational combination therapy being studied for the treatment of advanced solid tumors, including urothelial carcinoma. CVL006 is an investigational drug; its precise modality and mechanism of action are not fully disclosed in publicly available sources. Enfortumab vedotin is an antibody-drug conjugate (ADC) composed of a human IgG1 monoclonal antibody targeting Nectin-4 linked to monomethyl auristatin E (MMAE), a microtubule-disrupting cytotoxic agent. Following binding to Nectin-4 on cancer cells, enfortumab vedotin is internalized and MMAE is released, inducing cell cycle arrest and apoptosis. The combination is being tested in dose escalation and dose optimization clinical trials primarily as first-line treatment or for refractory advanced cancers[1][2].
- Brand names
- Padcev
- Other names
- CVL006 combined with enfortumab vedotinCVL-006 combined with enfortumab vedotinCVL 006 combined with enfortumab vedotin
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on CVL006 + enfortumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVL006 + enfortumab vedotin.